Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype.

[1]  B. Maron,et al.  Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy , 2007 .

[2]  G. Boriani,et al.  Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. , 2005, Journal of the American College of Cardiology.

[3]  W. Mckenna,et al.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.

[4]  B. Maron.  Diagnosis and management of hypertrophic cardiomyopathy , 2004 .

[5]  P. Elliott,et al.  Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. , 2003, The Journal of clinical investigation.

[6]  Christine E Seidman,et al.  Phenotypic diversity in hypertrophic cardiomyopathy. , 2002, Human molecular genetics.

[7]  A. Gomes,et al.  Functional Analysis of a Troponin I (R145G) Mutation Associated with Familial Hypertrophic Cardiomyopathy* , 2002, The Journal of Biological Chemistry.

[8]  C. Canter,et al.  Cardiac transplantation for pediatric restrictive cardiomyopathy: presentation, evaluation, and short-term outcome. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  B. Brenner,et al.  Mutation of the myosin converter domain alters cross-bridge elasticity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[11]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[12]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[13]  T. Hewett,et al.  Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[14]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[15]  H. Watkins,et al.  Altered Regulatory Properties of Human Cardiac Troponin I Mutants That Cause Hypertrophic Cardiomyopathy* , 2000, The Journal of Biological Chemistry.

[16]  W. Mckenna,et al.  Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. , 2000, The American journal of cardiology.

[17]  J B Seward,et al.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy. , 2000, Circulation.

[18]  J. Seidman,et al.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[19]  M. Gautel,et al.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. , 2000, Circulation.

[20]  Mario J. Garcia,et al.  New Doppler echocardiographic applications for the study of diastolic function. , 1998, Journal of the American College of Cardiology.

[21]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[22]  E. Topol.  Textbook of Cardiovascular Medicine , 1997 .

[23]  A. Angelini,et al.  Morphologic spectrum of primary restrictive cardiomyopathy. , 1997, The American journal of cardiology.

[24]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[25]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[26]  I. Belenkie,et al.  Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. , 1995, Circulation.

[27]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[28]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[29]  M. Frenneaux,et al.  Mechanisms of exercise limitation in hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[30]  Y. Hirota,et al.  Spectrum of restrictive cardiomyopathy: report of the national survey in Japan. , 1990, American heart journal.

[31]  W. Mckenna,et al.  Determinants of exercise capacity in hypertrophic cardiomyopathy. , 1989, Journal of the American College of Cardiology.

[32]  J. Child,et al.  The restrictive cardiomyopathies. , 1988, Cardiology clinics.

[33]  W. McKenna,et al.  Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. , 1983, Journal of the American College of Cardiology.

[34]  J. Gottdiener,et al.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. , 1981, The American journal of cardiology.

[35]  American Society of Echocardiography , 2022 .